Chemioterapia neoadjuvante dell'istiocitoma fibroso maligno delle estremita

10 anni di esperienze (1983-1992) all'Istituto Ortopedico Rizzoli

Translated title of the contribution: Neoadjuvant chemotherapy in malignant fibrous histiocytoma of the limbs: 10 years of experience (1983-1992) at the Rizzoli Orthopedic Institute

G. Bacci, S. Ferrari, P. Picci, C. Forni, D. Donati, M. Manfrini, N. Baldini, D. Iantorno, M. Campanacci

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

During the period September 1983 to December 1991, 47 patients with nonmetastatic malignant fibrous histiocytoma (MFH) of the limbs were treated using 3 different protocols of neoadjuvant chemotherapy activated at successive intervals. Surgery consisted of limb salvage in 41 cases and amputation in 6. After a mean follow-up of 6.5 years 33 patients (70%) had been continuously disease-free and 14 had undergone relapses. In the latter group the first sign of recurrence was metastasis in 12 cases and local recurrence in 2 cases. These results are distinctly better than those obtained in 20 patients treated during the same period using surgery alone (24% of disease-free survival and 30% local recurrence), and compared to those obtained in an earlier study in which surgery was associated with postoperative chemotherapy alone (59% of disease-free survival and 25% of local recidivation). The authors conclude that, as already observed in the case of osteosarcoma, neoadjuvant chemotherapy can significantly improve prognosis even in patients with bone MFH localised in the limbs. Moreover, given that, contrary to adjuvant chemotherapy, associated chemotherapy is effective not only in controlling the microscopic disease but also reducing the incidence of local recurrence, it enables amputation to be avoided in the majority of patients.

Original languageItalian
Pages (from-to)135-146
Number of pages12
JournalMinerva Medica
Volume87
Issue number4
Publication statusPublished - Apr 1996

Fingerprint

Malignant Fibrous Histiocytoma
Orthopedics
Extremities
Recurrence
Drug Therapy
Amputation
Disease-Free Survival
Limb Salvage
Osteosarcoma
Adjuvant Chemotherapy
Neoplasm Metastasis
Bone and Bones
Incidence

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Chemioterapia neoadjuvante dell'istiocitoma fibroso maligno delle estremita : 10 anni di esperienze (1983-1992) all'Istituto Ortopedico Rizzoli. / Bacci, G.; Ferrari, S.; Picci, P.; Forni, C.; Donati, D.; Manfrini, M.; Baldini, N.; Iantorno, D.; Campanacci, M.

In: Minerva Medica, Vol. 87, No. 4, 04.1996, p. 135-146.

Research output: Contribution to journalArticle

@article{3c46299e5ab747fea6af575a85fcbfe6,
title = "Chemioterapia neoadjuvante dell'istiocitoma fibroso maligno delle estremita: 10 anni di esperienze (1983-1992) all'Istituto Ortopedico Rizzoli",
abstract = "During the period September 1983 to December 1991, 47 patients with nonmetastatic malignant fibrous histiocytoma (MFH) of the limbs were treated using 3 different protocols of neoadjuvant chemotherapy activated at successive intervals. Surgery consisted of limb salvage in 41 cases and amputation in 6. After a mean follow-up of 6.5 years 33 patients (70{\%}) had been continuously disease-free and 14 had undergone relapses. In the latter group the first sign of recurrence was metastasis in 12 cases and local recurrence in 2 cases. These results are distinctly better than those obtained in 20 patients treated during the same period using surgery alone (24{\%} of disease-free survival and 30{\%} local recurrence), and compared to those obtained in an earlier study in which surgery was associated with postoperative chemotherapy alone (59{\%} of disease-free survival and 25{\%} of local recidivation). The authors conclude that, as already observed in the case of osteosarcoma, neoadjuvant chemotherapy can significantly improve prognosis even in patients with bone MFH localised in the limbs. Moreover, given that, contrary to adjuvant chemotherapy, associated chemotherapy is effective not only in controlling the microscopic disease but also reducing the incidence of local recurrence, it enables amputation to be avoided in the majority of patients.",
keywords = "chemotherapy, neoadjuvant, histiocytoma, malignant fibrous, imputation, limb salvage",
author = "G. Bacci and S. Ferrari and P. Picci and C. Forni and D. Donati and M. Manfrini and N. Baldini and D. Iantorno and M. Campanacci",
year = "1996",
month = "4",
language = "Italian",
volume = "87",
pages = "135--146",
journal = "Minerva Medicolegale e Archivio di Antropologia Criminale",
issn = "0026-4806",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "4",

}

TY - JOUR

T1 - Chemioterapia neoadjuvante dell'istiocitoma fibroso maligno delle estremita

T2 - 10 anni di esperienze (1983-1992) all'Istituto Ortopedico Rizzoli

AU - Bacci, G.

AU - Ferrari, S.

AU - Picci, P.

AU - Forni, C.

AU - Donati, D.

AU - Manfrini, M.

AU - Baldini, N.

AU - Iantorno, D.

AU - Campanacci, M.

PY - 1996/4

Y1 - 1996/4

N2 - During the period September 1983 to December 1991, 47 patients with nonmetastatic malignant fibrous histiocytoma (MFH) of the limbs were treated using 3 different protocols of neoadjuvant chemotherapy activated at successive intervals. Surgery consisted of limb salvage in 41 cases and amputation in 6. After a mean follow-up of 6.5 years 33 patients (70%) had been continuously disease-free and 14 had undergone relapses. In the latter group the first sign of recurrence was metastasis in 12 cases and local recurrence in 2 cases. These results are distinctly better than those obtained in 20 patients treated during the same period using surgery alone (24% of disease-free survival and 30% local recurrence), and compared to those obtained in an earlier study in which surgery was associated with postoperative chemotherapy alone (59% of disease-free survival and 25% of local recidivation). The authors conclude that, as already observed in the case of osteosarcoma, neoadjuvant chemotherapy can significantly improve prognosis even in patients with bone MFH localised in the limbs. Moreover, given that, contrary to adjuvant chemotherapy, associated chemotherapy is effective not only in controlling the microscopic disease but also reducing the incidence of local recurrence, it enables amputation to be avoided in the majority of patients.

AB - During the period September 1983 to December 1991, 47 patients with nonmetastatic malignant fibrous histiocytoma (MFH) of the limbs were treated using 3 different protocols of neoadjuvant chemotherapy activated at successive intervals. Surgery consisted of limb salvage in 41 cases and amputation in 6. After a mean follow-up of 6.5 years 33 patients (70%) had been continuously disease-free and 14 had undergone relapses. In the latter group the first sign of recurrence was metastasis in 12 cases and local recurrence in 2 cases. These results are distinctly better than those obtained in 20 patients treated during the same period using surgery alone (24% of disease-free survival and 30% local recurrence), and compared to those obtained in an earlier study in which surgery was associated with postoperative chemotherapy alone (59% of disease-free survival and 25% of local recidivation). The authors conclude that, as already observed in the case of osteosarcoma, neoadjuvant chemotherapy can significantly improve prognosis even in patients with bone MFH localised in the limbs. Moreover, given that, contrary to adjuvant chemotherapy, associated chemotherapy is effective not only in controlling the microscopic disease but also reducing the incidence of local recurrence, it enables amputation to be avoided in the majority of patients.

KW - chemotherapy, neoadjuvant

KW - histiocytoma, malignant fibrous

KW - imputation

KW - limb salvage

UR - http://www.scopus.com/inward/record.url?scp=0030013277&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030013277&partnerID=8YFLogxK

M3 - Articolo

VL - 87

SP - 135

EP - 146

JO - Minerva Medicolegale e Archivio di Antropologia Criminale

JF - Minerva Medicolegale e Archivio di Antropologia Criminale

SN - 0026-4806

IS - 4

ER -